Navigation Links
Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment
Date:11/1/2011

BARCELONA, Spain, November 2, 2011 /PRNewswire/ --

In preparation for its European launch of Benlysta, the first FDA approved Lupus drug in 50 years, Human Genome Sciences (HGS) needed a customer relationship management (CRM) system to arm its newly formed European commercial sales team. The company had a long list of selection criteria including ease of use, flexibility, mobility, industry-specific functionality, speed, and low system maintenance. Veeva CRM - the fastest growing pharma CRM solution in the world - had proven itself already at HGS' U.S. headquarters, but also offered international synergy for HGS Europe. After a thorough market analysis, HGS selected cloud-based Veeva CRM for all specialty care sales reps and medical science liaisons in Germany, Spain and France.

In June, HGS' German office began implementing Veeva CRM and finished the project in six weeks - two weeks ahead of schedule. HGS cited Veeva's strong pharmaceutical industry expertise and understanding of HGS' sales model as key to the smooth implementation. Implementing with a single flexible system across Europe will ensure HGS is able to roll out the system quickly and at a very low cost in additional countries, including Spain and France which are scheduled to deploy Veeva CRM next. "Veeva CRM is extremely intuitive, and fully embraced by our field teams in Germany who are already up and running on the system," said Kevin Crowe, associate director, Marketing and Sales Operations, Europe at HGS. "Veeva CRM will allow us to improve customer traction by enabling our reps to more effectively measure calls and profile customers. Additionally, Veeva CRM is a great system for improving customer targeting, making us more efficient at turning non-prescribers into advocates!"  

Before choosing Veeva CRM, HGS considered all of the top offerings but had concerns that their single tenant architectures would limit flexibility. "On-site and hosted solutions are dinosaurs,
'/>"/>

SOURCE Veeva Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
2. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
3. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
4. UC Riverside researcher develops novel method to grow human embryonic stem cells
5. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
7. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Conference
9. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
10. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
11. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 Increasing its efforts to ... launches its first three episodes of The GMO TRUTH podcast ... this month, as it continues its mission to discover the ... project's first phase, to “uncover the truth about the GMOs ... , The GMO Truth Podcast is an expansion of the ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... financial results for the quarter,ended March 31, 2008., ... net revenue of,$372.2 million compared to net revenue of ... increase was primarily due to increased,product and service revenue ...
... dynamic stabilization,nonfusion segments skyrocketed, according to Millennium Research Group,s US ... ... Millennium Research Group,s,(MRG) US Spine Marketrack(TM) results indicate that ... and surgeon,awareness and new product releases starting in Q3 2007 ...
... will be enrolled to evaluate R7128 1500mg BID in HCV,genotypes 2 and 3 prior ... ... 1:00 PM ET (US) ... CEST (Milan) --, PRINCETON, N.J. and MILAN, Italy, April 24 ,Pharmasset, Inc. (Nasdaq: ...
Cached Biology Technology:Inverness Medical Innovations Announces First Quarter 2008 Results 2Inverness Medical Innovations Announces First Quarter 2008 Results 3Inverness Medical Innovations Announces First Quarter 2008 Results 4Inverness Medical Innovations Announces First Quarter 2008 Results 5Inverness Medical Innovations Announces First Quarter 2008 Results 6Inverness Medical Innovations Announces First Quarter 2008 Results 7Inverness Medical Innovations Announces First Quarter 2008 Results 8Inverness Medical Innovations Announces First Quarter 2008 Results 9Inverness Medical Innovations Announces First Quarter 2008 Results 10Adoption of Spinal Nonfusion Technologies Doubled in One Year 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 3Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 4Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 5
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... standing member of the IOF Board and leading researcher ... the recipient of the prestigious Pierre Delmas Award. The ... Osteoporosis & Osteoarthritis (ESCEO13-IOF), currently being held in Rome, ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ...
... the University of Alberta are abuzz after using fruit ... caffeine,s lethal effects on cancer cellsresults that could one ... Previous research has established that caffeine interferes with ... finding that has generated interest in using the stimulant ...
... past, now has had its genome sequenced, providing a ... the adaptation from an aquatic environment to land. A ... Director of Molecular Genetics at the Benaroya Research Institute ... the University of Washington, will publish "The African coelacanth ...
Cached Biology News:Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... Total Canine Endostatin. Canine Cytokine ... products include a line of enzyme-linked ... reagents used for multiple research applications. ... are ultra-sensitive, quick and dependable assays. ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: